Pendulum Therapeutics Raises $111M to Revolutionize Microbiome Science and Diabetes Care

Pendulum Therapeutics, the leading innovator in microbiome science, has made headlines with its recent fundraising achievement by securing $111,000,000 in new capital. This significant investment underscores the company's unwavering commitment to revolutionizing metabolic health through groundbreaking probiotic formulations and advanced microbiome research. At the core of Pendulum Therapeutics’ innovation is its flagship product, Pendulum Akkermansia—the first novel species introduced into the probiotic market in over 50 years—which has distinguished itself as the first and only probiotic clinically proven to lower A1C and blood glucose levels in individuals with type 2 diabetes. Pendulum Akkermansia works by stimulating the natural production of GLP-1, a hormone integral to maintaining balanced insulin and blood sugar levels, thereby offering a transformative solution for millions affected by diabetes. With this new funding, Pendulum Therapeutics is poised to expand its research and development initiatives, further refine its proprietary formulations, and broaden its market presence internationally. The capital will be allocated to advancing clinical trials, fostering innovative research partnerships, and scaling production capabilities to meet growing consumer demand for effective, science-backed metabolic health solutions. As Pendulum Therapeutics continues to leverage cutting-edge research and a strong intellectual property portfolio, its mission remains clear: to provide consumers worldwide with reliable, research-based products that support optimal metabolic function and overall wellness. This fresh injection of capital represents not only a financial milestone but also a vital step forward in the company’s ongoing quest to transform the landscape of metabolic health and empower individuals to take control of their well-being.